Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, discuss key inflection points in frontline treatment of EGFR-mutant NSCLC.
Back
Evolving Decision-Making in EGFR-Mutant Advanced NSCLC
Jonathan Riess, MD, MS, and Nicolas Villanueva, MD, discuss evolving frontline and sequencing strategies in EGFR-mutant non–small cell lung cancer.
Evolving Decision-Making in EGFR-Mutant Advanced NSCLC
Episodes
All
All
Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, examine how overall survival data from recent trials are influencing treatment decisions.
Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, examine how high-risk disease is defined and applied in clinical practice.
Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, outline the role of ctDNA in guiding treatment decisions.
Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, discuss treatment sequencing following progression on intensified regimens.
Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, discuss how antibody-drug conjugates are shaping treatment strategies after progression.
Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, discuss the future of personalized treatment in EGFR-mutant NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
2
T-DXd Improves PFS in First-Line HER2-Mutant NSCLC
3
FDA Grants Fast Track Designation to Sapanisertib and Serabelisib Plus Paclitaxel in Advanced Endometrial Cancer
4
Dr Viansone on ADC Sequencing in Metastatic HER2+ Breast Cancer
5